Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504623 | 0.85 | CAPN1 (0.60) | CAPN1DAOPARP1DGAT1TSHR | |
| SCHEMBL21707883 | 0.78 | CAPN1 (0.77) | CAPN1DAOPARP1TSHR | |
| SCHEMBL30266499 | 0.77 | CAPN1 (0.41) | CAPN1DAODGAT1MAPK1 | |
| SCHEMBL16431613 | 0.76 | DAO (0.42) | CAPN1DAOPARP1DGAT1TSHR | |
| SCHEMBL12775584 | 0.70 | TSHR (0.35) | DAODGAT1TSHR | |
| SCHEMBL13754481 | 0.67 | HRH4 (0.55) | DAODGAT1TSHRPDE3BPDE3A | |
| SCHEMBL12598586 | 0.66 | AOC3 (0.47) | DAOPARP1DGAT1 | |
| SCHEMBL20341002 | 0.66 | DAO (0.33) | CAPN1DAODGAT1TSHRPDE3B | |
| SCHEMBL14012158 | 0.66 | DGAT1 (0.38) | DAODGAT1TSHRGPR84 | |
| SCHEMBL17285583 | 0.66 | PPARG (0.40) | CAPN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | CAPN1 81/4885DAO 2868/4885PARP1 437/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | CAPN1 81/4885DAO 2868/4885PARP1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.